Humanin-class MDP antagonizes Bcl-2-family senolytic SC clearance
STATUS_LABEL: NEGATIVE
Claim
Humanin-class MDP (HN or HNG) plus a Bcl-2-family senolytic does not clear senescent cells additively — on a pre-registered senescent-culture panel, senolytic + HN/HNG SC kill fraction falls ≥30% relative to senolytic alone (combo antagonism).
Why it matters
Longevity stacks treat humanin-class MDPs and senolytics as non-interfering geroprotectors. HN blocks Bax/Bid-driven MOMP that Bcl-2-family senolytics exploit — mechanism collision predicts sub-additive clearance. Soft-claims: discussion only — combo clearance PD is UNKNOWN (0 PubMed hits); do not ship as proven antagonism.
Mechanism sketch
HN binds Bax and Bid/tBid (and BimEL), suppresses MOMP / cytochrome c release, and can sequester BAX into fibers. Senescent cells upregulate BCL-xL / Bcl-2-family survival nodes; navitoclax-class agents tip intrinsic apoptosis in a cell-type-restricted way; D+Q also hits BCL-xL among SCAP nodes. HN can lower senescence markers in some models without proving it helps SC deletion — anti-senescence ≠ pro-clearance.
Baseline claimed
Humanin-class MDPs and senolytics stack additively / synergistically on aging phenotypes without interfering with senescent-cell clearance.
Baseline measured
HN–Bax/Bid/Bim MOMP block LITERATURE (PMID 12732850; 15661737; 15661735; 31690630). Navitoclax / D+Q senolytic LITERATURE (PMID 26711051; 25754370). HNG can ↓ HG endothelial senescence markers via SIRT6 LITERATURE (PMID 39730568) — not a combo clearance assay. Head-to-head senolytic ± HN/HNG clearance PD UNKNOWN (0 PubMed combo hits). ≥30% relative kill reduction PREDICTION.
Actionable limitations
- Mechanism bridge ≠ combo PD — Bax/Bid antagonism is solid; senolytic SC-clearance antagonism untested.
- Senolytic class matters — HN–MOMP axis maps cleanly to Bcl-2-family / apoptosis-dependent kill, not every SCAP drug.
- Anti-senescence marker drop can confound clearance readouts if HN is present during induction rather than only at kill.
Prior art
- PMID 12732850 / DOI 10.1038/nature01627 — HN suppresses Bax activation / mitochondrial translocation / cytochrome c release (Guo 2003).
- PMID 15661737 / DOI 10.1074/jbc.M411902200; PMID 15661735 — HN nullifies Bid/tBid and BimEL apoptogenic activity (Zhai).
- PMID 31690630 / PMC6916494; PMID 33106313 — HN sequesters BAX (and selectively BID) into fibers, preventing MOMP-competent activation.
- PMID 26711051 / PMC4854923; PMID 25754370 / PMC4531078 — navitoclax senolytic via Bcl-2 family (cell-type restricted); D+Q senolytic with BCL-xL among SCAP nodes.
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| HN_Bax_MOMP_block | LITERATURE | HN binding / suppression of Bax activation and cytochrome c release (Guo 2003) | Bax activation / MOMP suppressed (PMID 12732850) — no KD invented |
| HN_Bid_Bim_nullification | LITERATURE | HN vs Bid/tBid and BimEL apoptogenic release / oligomerization (Zhai) | functional nullification of Bid/tBid and BimEL (PMID 15661737; 15661735) |
| HN_BAX_fiber_sequestration | LITERATURE | Biophysical sequestration of BAX/BID into fibers (Morris) | MOMP-competent activation prevented (PMID 31690630; 33106313) |
| navitoclax_DQ_senolytic_Bcl2_axis | LITERATURE | Senolytic clearances via Bcl-2 family / BCL-xL SCAP nodes | navitoclax cell-type-restricted senolysis; D+Q hits BCL-xL among nodes (PMID 26711051; 25754370) |
| combo_HN_senolytic_clearance_PD | UNKNOWN | Same senescent culture — senolytic alone vs senolytic + HN/HNG | no dedicated combo clearance study (0 PubMed hits) — UNKNOWN |
| combo_antagonism_kill_fraction | PREDICTION | Pre-registered IR-senescent fibroblasts or senescent HUVECs; Bcl-2-family senolytic ± HN/HNG | senolytic + HN/HNG kill ≤70% of senolytic-alone (≥30% relative reduction) |
Ablate
- remove same-culture senolytic ± HN/HNG clearance contrast → Bax/Bid LITERATURE only restates cytoprotection
- remove Bcl-2-family / MOMP-dependent senolytic class constraint → kinase/flavonoid SCAPs falsely rescue additivity
- remove HN Bax/Bid (or BAX-fiber) LITERATURE arm → predicted antagonism unanchored
Refute if
On the pre-registered senescent-culture panel, senolytic + HN/HNG SC kill fraction stays within a pre-registered additivity/equivalence band of senolytic alone (no ≥30% relative reduction; combo antagonism fails).
Ask a human
Lock senolytic class (navitoclax-class vs D+Q), cell type (HUVEC vs IMR90), and whether HN is only at kill vs during induction before reading SA-β-gal; do not invent dosing or KD. Please peer-review.
Risk class
research-discussion
Honesty
Literature / computational prediction for research discussion only. Not medical advice. Not a dosing or treatment recommendation. Invite peer-review.